Nephron Adjusts Revvity's Price Target to $124 From $120
Revvity (RVTY) has an average rating of outperform and price targets ranging from $100 to $162, according to analysts polled by Capital IQ. Price: 105.09, Change: +3.58, Percent Change: +3.53
Iterum Therapeutics Resubmits New Drug Application to U.S. FDA for Oral Sulopenem
Agilent Names Simon May to Lead Diagnostics and Genomics Group
Agilent Technologies, Inc. (NYSE:A) today announced Simon May has been named president of the company's Diagnostics and Genomics Group (DGG). May, previously executive vice president and president of the Life Science
Loop Media Selected by RadNet to Provide Ad Sales Services, Branded Channels, and Customized Signage Across RadNetTV
Loop Media, Inc. ("Loop Media") (NYSE:LPTV), a leading multichannel streaming CTV platform that provides curated music videos, sports highlights, news, premium entertainment channels and digital signage for
Revvity Beats Quarterly Estimates on Demand for Diagnostic Equipment
Effective May 1, 2024, Bio-Techne Will Enter Into A Distribution Agreement With Thermo Fisher Scientific In Europe
Under this agreement, Thermo Fisher, through the European arm of its Fisher Scientific Channel, will distribute Bio-Techne's extensive portfolio of innovative products, including antibodies, proteins,